-

Robbins LLP is Investigating Allegations that the Officers and Directors of Beta Bionics, Inc. (BBNX) Violated Securities Laws and Breached Fiduciary Duties to Shareholders

SAN DIEGO--(BUSINESS WIRE)--Shareholder Rights law firm Robbins LLP is investigating Beta Bionics, Inc. (NASDAQ: BBNX) to determine whether certain Beta Bionics officers and directors violated securities laws and breached fiduciary duties to shareholders. Beta Bionics is a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes.

Robbins LLP is Investigating Allegations that the Officers and Directors of Beta Bionics, Inc. (BBNX) Violated Securities Laws and Breached Fiduciary Duties to Shareholders

Share

On January 8, 2026, Beta Bionics issued preliminary, unaudited fourth quarter 2025 topline financial results and key operating metrics. The Company reported that new patient starts for the quarter were expected to be at least 5,581, representing year-over-year growth of at least 36%. The reported figure was below analyst expectations and reflected a slowdown from the prior quarter, when Beta Bionics reported 68% year-over-year growth in new patient starts. Following the announcement, Beta Bionics’ stock price declined more than 35% on January 9, 2026.

What Now: If you lost money in your investment of Beta Bionics, Inc., contact Robbins LLP for more information about your rights.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Contact us to learn more:

Aaron Dumas, Jr.
(800) 350-6003
adumas@robbinsllp.com
Shareholder Information Form

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. Since our inception, we have obtained over $1 billion for shareholders.

To be notified if a class action against Beta Bionics, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Robbins LLP

NASDAQ:BBNX

Release Versions
$Cashtags

Contacts

Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Social Media Profiles
More News From Robbins LLP

PNR Stockholders Have Rights – If You Lost Money Investing in Pentair plc Contact Robbins LLP for Information About Recovering Your Losses

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds investors that a securities class action has been filed on behalf of all persons and entities that purchased or otherwise acquired Pentair plc (NYSE: PNR) securities between April 28, 2026 and July 14, 2026 (the "Class Period"). Pentair provides various water solutions, such as filtration, water supply pumps, and fluid treatment products. The lawsuit alleges that Pentair misled investors regarding the destocking of its inventory in the Pool channe...

Robbins LLP Urges HDB Stockholders Who Lost Money Investing in HDFC Bank Limited to Contact the Firm for Information About Leading the Class Action

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired HDFC Bank Limited (NYSE: HDB) securities between July 17, 2023 and May 26, 2026 (the "Class Period"). HDFC is an Indian financial services conglomerate and banking company headquartered in Mumbai. The complaint alleges that HDFC Bank camouflaged payments as marketing spend to pay higher interest to a state f...

Robbins LLP Urges REPL Stockholders to Contact the Firm for Information About the Class Action Against Replimune Group, Inc.

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Replimune Group, Inc. (NASDAQ: REPL) securities between October 20, 2025 and April 10, 2026 ("Class Period"). Replimune purports to be a clinical-stage biotechnology company focused on novel oncolytic immunotherapies. According to the complaint, the Company’s lead product candidate is RP1 (vusolimogene oderp...
Back to Newsroom